• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Solana Company

    11/12/25 4:05:14 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    NT 10-Q 1 tm2530846d1_nt10q.htm NT 10-Q

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    Commission File Number 001-42612

     

    CUSIP Number: G2868C 101

     

    (Check One):  

    ¨ Form 10-K  ¨ Form 20-F ¨ Form 11-K x Form 10-Q

    ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR

         
        For Period Ended: September 30, 2025
         
        ¨ Transition Report on Form 10-K
         
        ¨ Transition Report on Form 20-F
         
        ¨ Transition Report on Form 11-K
         
        ¨ Transition Report on Form 10-Q
         
        For the Transition Period Ended:

     

     
     
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

     

    PART I – REGISTRANT INFORMATION

     

     

    SOLANA COMPANY

    Full Name of Registrant

     

    Helius Medical Technologies, Inc.

    Former Name, if Applicable

     

    642 Newtown Yardley Road, Suite 100

    Address of Principal Executive Office (Street and Number)

     

    Newtown, PA 18940

    City, State and Zip Code

     

     

     

     

     

     

     

    PART II – RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III – NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Registrant”) has determined that it is not able to file its quarterly report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) within the prescribed time period without unreasonable efforts or expense. As disclosed in the Registrant’s Current Report on Form 8-K filed with the SEC on October 16, 2025, the Audit Committee of the Board of Directors of the Registrant received the resignation of Baker Tilly US, LLP as the Company’s independent registered public accounting firm, effective October 15, 2025. On October 15, 2025, the Committee approved the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately. The Registrant, while making efforts to expedite the process, requires additional time to finalize the review of the financial statements to be included in the Form 10-Q. While there can be no assurance, the Company anticipates that the Form 10-Q will be filed as soon as practicable and in any event on or prior to the fifth calendar day following the prescribed due date.

     

     

     

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification:
               
      Jeffrey S. Mathiesen   (215)   944-6201
      (Name)   (Area code)   (Telephone Number)
       
    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
       
      x Yes ¨ No
       
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? x Yes ¨ No
       
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
       
      As previously disclosed in the Registrant’s Current Report on Form 8-K on September 15, 2025, as a result of the Registrant’s PIPE Offerings adoption of a Solana-centric Digital Asset Treasury and the related transactions, the Registrant anticipates significant changes in its results of operations for the quarter ended September 30, 2025, as will be reflected in the Form 10-Q. However, until the review is complete and the results are evaluated by the Registrant’s management and its independent registered public accounting firm, the Registrant cannot currently quantify these changes to its preliminary results of operations or financial condition for the quarter ended September 30, 2025.

     

    Forward-Looking Statements

     

    Certain statements made herein are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words and phrases such as “will”, “may”, “should”, “future”, “promptly”, “expect”, “estimate”, “anticipate,” “intends”, “plans”, “subject to”, and “change” and other similar expressions that predict or indicate future events or trends or that are not statements of historical fact. Such statements may include, but are not limited to, the filing of the Form 10-Q and the results of the ongoing review. These statements are based on current expectations on the date hereof and involve a number of risks and uncertainties that may cause actual results to differ significantly. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, including without limitation a material delay in the Company’s financial reporting, including the possibility that the Company will not be able to file its Form 10-Q within the five-day extension permitted by the rules of the SEC, and the possibility that the ongoing review may identify errors or control deficiencies in the Company’s accounting practices. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise.

     

     

     

     

    Solana Company

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 12, 2025 By: /s/ Jeffrey S. Mathiesen
        Name: Jeffrey S. Mathiesen
        Title: Chief Financial Officer

     

     

     

    Get the next $HSDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jiang Cosmo Yi

    3 - Solana Co (0001610853) (Issuer)

    10/31/25 6:51:45 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Chee Choon Wee claimed ownership of 6,830,402 shares (SEC Form 3)

    3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    9/25/25 5:00:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    7/3/25 8:00:26 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    SEC Filings

    View All

    SEC Form NT 10-Q filed by Solana Company

    NT 10-Q - Solana Co (0001610853) (Filer)

    11/12/25 4:05:14 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Solana Co (0001610853) (Filer)

    11/5/25 9:29:13 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Solana Co (0001610853) (Filer)

    11/3/25 9:25:14 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Noble Capital Markets initiated coverage on Helius Medical with a new price target

    Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

    3/24/21 8:02:45 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

    LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

    2/12/21 8:21:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solana Company to Release Third Quarter Operating Results on November 18, 2025

    NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its third quarter operating results on Tuesday, November 18, 2025, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Tuesday, November 18, 2025Time:4:30 p.m. Eastern TimeWebcast:Click here   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Comp

    11/12/25 4:30:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Announces Intent to Tokenize HSDT Shares on Superstate's Opening Bell

    NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced its plans to tokenize shares of its HSDT fund on Superstate's Opening Bell platform. The initiative marks a major step forward in the Company's strategy to modernize access to capital markets through regulated, onchain infrastructure. Upon launch, shareholders will be able to hold and transfer tokenized representations of HSDT shares on Superstate's Opening Bell, enabling 24/7 trading, real-time settlement, and enhanced global liqu

    11/12/25 8:30:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Clear Street's Disruptive Technology Conference Convenes this Month in Palm Beach

    Invitation-only event features CEOs, investors and innovators across AI, Digital Assets, Fintech and beyond Keynote speakers Michael Saylor and Eric Trump highlight lineup of thought leaders NEW YORK and PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Clear Street, ("Clear Street", "the Company") a cloud-native financial infrastructure technology firm on a mission to give sophisticated investors access to every asset in every market, will host its Disruptive Technology Conference on November 19–20, 2025, at the Four Seasons Resort Palm Beach, Florida. The two-day, invitation-only event brings together a select group of CEOs, institutional investors and pioneering industry leaders fo

    11/7/25 2:30:00 PM ET
    $ABTC
    $BKKT
    $CLSK
    EDP Services
    Technology
    Finance: Consumer Services
    Finance

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Solana Company to Release Third Quarter Operating Results on November 18, 2025

    NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its third quarter operating results on Tuesday, November 18, 2025, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Tuesday, November 18, 2025Time:4:30 p.m. Eastern TimeWebcast:Click here   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Comp

    11/12/25 4:30:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

    NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.   "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I

    11/18/24 8:01:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

    NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus

    8/6/24 4:36:06 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

    NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

    5/20/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care